The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXaar Regulatory News (XAR)

Share Price Information for Xaar (XAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 114.50
Bid: 116.00
Ask: 121.50
Change: 0.00 (0.00%)
Spread: 5.50 (4.741%)
Open: 114.50
High: 114.50
Low: 114.50
Prev. Close: 114.50
XAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Board Change

23 Feb 2024 10:30

RNS Number : 1814E
Xaar PLC
23 February 2024
 

23 February 2024

Xaar plc

Board Change

Xaar plc, ("the Company" or "Xaar"), a leading inkjet printing technology group, announces today the appointment of Stuart Widdowson to the Board as a Non-Executive Director effective from 27 February 2024.

Mr Widdowson is appointed as a representative of Odyssean Capital LLP ("Odyssean"), pursuant to a relationship agreement between the Company and Odyssean. The key terms are summarised in the notes below.

Mr Widdowson is the Managing Partner of Odyssean Capital, which he founded in 2017. From 2009 until 2017, he was lead fund manager of Strategic Equity Capital plc, which experienced a turnaround in its performance and rating during his tenure. He began his career as a strategy consultant undertaking commercial due diligence and strategy projects for private equity and corporate clients, before working for HgCapital, a leading private equity investor.

As at the last practicable date the total shareholding of funds managed by Odyssean Capital was 13,175,000 ordinary shares in the Company ("Ordinary Shares") representing approximately 16.6 per cent. of the Company's share capital. Additionally, Mr Widdowson beneficially owns 25,000 Ordinary Shares and the joint venture partner of Odyssean Capital, Harwood Capital, owns 1,050,000 Ordinary Shares.

Notes:

A summary of the key terms of the Relationship Agreement is as follows:

· Xaar has granted Odyssean the right to appoint Mr Widdowson to be a Director of the Company for appointment to the Board (the "Nominated Director") for so long as Odyssean has the right to exercise at least 10% or more of the Company's ordinary shares or voting rights attaching to the ordinary shares;

· Odyssean undertakes to, inter alia: (1) conduct all transactions and relationships with any member of Xaar's group on an arm's length basis; (2) not take any action which would have the effect of preventing Xaar or any member of Xaar's group from carrying on business independently of Odyssean or its associates; (3) not influence the day-to-day running of the Company (save through Mr Widdowson's role as the Nominated Director) and (4) not vote to prevent Xaar being managed in accordance with the principles of good governance set out in the UK Corporate Governance Code; and

· the Relationship Agreement will terminate (1) on the date upon which Odyssean ceases to hold at least 10% of the ordinary shares of the Company or the voting rights attaching to the ordinary shares of the Company; (2) on six months' notice written notice by either party at any time or immediately upon written notice in the event of a material breach of the Relationship Agreement; or (3) in the event that the Company's ordinary shares cease to be listed on the Official List or another recognised UK stock exchange.

Pursuant to Listing Rule 9.6.13, it is confirmed that Mr Widdowson was a director and shareholder of Durendal Limited, a fund management business, which was wound up in 2015. His shareholding was acquired by the majority shareholder and the cash was distributed to all shareholders before the company was voluntarily liquidated.

There is no additional information required to be disclosed pursuant to Listing Rule 9.6.13 in relation to the appointment of Stuart Widdowson to the Board.

Enquiries:

Xaar plc

+44 (0) 1223 423 663 

Ian Tichias, Chief Financial Officer

John Mills, Chief Executive Officer

 

Teneo Communications

Giles Kernick

Olivia Lucas

+44 (0) 207 353 4200

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOATTMPTMTTTBFI
Date   Source Headline
22nd Apr 202410:51 amRNSAnnual Financial Report
2nd Apr 202412:00 pmRNSTotal Voting Rights
1st Mar 202410:15 amRNSTotal Voting Rights
26th Feb 20249:00 amRNSHolding(s) in Company
23rd Feb 202410:30 amRNSBoard Change
1st Feb 20241:32 pmRNSTotal Voting Rights
29th Jan 202412:04 pmRNSHolding(s) in Company
12th Jan 20243:15 pmRNSBlock listing Interim Review
12th Jan 20247:00 amRNSNotification of Results & Full year Guidance
8th Jan 202412:36 pmRNSTotal Voting Rights
12th Dec 20239:00 amRNSNotification of Transactions of Directors & PDMRs
11th Dec 20233:00 pmRNSNotification of Transactions of Directors & PDMRs
1st Dec 202311:00 amRNSTotal Voting Rights
1st Dec 202310:00 amRNSDirector Declaration
29th Nov 20237:00 amRNSTrading Update
17th Nov 20234:07 pmRNSHolding(s) in Company
9th Nov 20231:53 pmRNSDirector/PDMR Shareholding
3rd Nov 202310:52 amRNSHolding(s) in Company
1st Nov 20234:03 pmRNSTotal Voting Rights
30th Oct 20237:00 amRNSBoard Changes
2nd Oct 202311:45 amRNSTotal Voting Rights
21st Sep 20233:16 pmRNSHolding(s) in Company
21st Sep 20239:57 amRNSHolding(s) in Company
19th Sep 20237:00 amRNS2023 Interim Results
11th Sep 20232:11 pmRNSHolding(s) in Company
11th Sep 202312:14 pmRNSHolding(s) in Company
11th Sep 202312:07 pmRNSHolding(s) in Company
11th Sep 202312:03 pmRNSHolding(s) in Company
11th Sep 202312:02 pmRNSHolding(s) in Company
11th Sep 202312:02 pmRNSHolding(s) in Company
7th Sep 20239:00 amRNSNotice of 2023 Half Year Results
1st Sep 20239:30 amRNSTotal Voting Rights
25th Aug 202312:13 pmRNSHolding(s) in Company
23rd Aug 202310:24 amRNSHolding(s) in Company
18th Aug 202310:30 amRNSChange of Auditor
17th Aug 202312:55 pmRNSHolding(s) in Company
3rd Aug 20237:00 amRNSTrading Update
1st Aug 20232:00 pmRNSTotal Voting Rights
28th Jul 20234:30 pmRNSHolding(s) in Company
5th Jul 20239:00 amRNSXaar plc - Commercial partnership with Quantica
4th Jul 20233:00 pmRNSBlock listing Interim Review
3rd Jul 20232:53 pmRNSTotal Voting Rights
1st Jun 202310:37 amRNSTotal Voting Rights
31st May 202311:30 amRNSResult of AGM
31st May 20239:00 amRNSBoard Changes
11th May 20235:41 pmRNSHolding(s) in Company
10th May 20233:10 pmRNSDirector/PDMR Shareholding
2nd May 202312:39 pmRNSTotal Voting Rights
24th Apr 20231:05 pmRNSAnnual Financial Report
3rd Apr 20234:51 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.